CEO and Founder of Invetx with the vision for Invetx to become the leading veterinary biotherapeutics company.
15+ years in various leadership roles in Marketing and R&D in the Animal Health industry and biotech. New product development for global markets with a focus to transfer and apply innovative technologies from human biotechnology to advance veterinary medicine.
Novartis Animal Health, Novartis Institute for Biomedical Research, Elanco/Lilly, Nexvet
Dr. med. vet., Ludwig Maximilians University Munich, Germany
PhD, Royal Veterinary College, University of London, UK
EMBA, London Business School, UK & Columbia Business School, NYC, US
Clinical and Regulatory Affairs, passionate about bringing Invetx’s portfolio of innovative veterinary biotherapeutics through the regulatory process to be available to practicing veterinarians and their patients.
35 years of experience in the management of R&D in the Animal Health Industry including many years in senior leadership positions; focused on bringing innovative veterinary medicines to the marketplace.
Pfizer Animal Health (now Zoetis), Nexvet Biopharma, Independent Consultant
BVetMed, Royal Veterinary College, University of London, UK
PhD, Royal Veterinary College, University of London, UK
Krishnan SampathSenior Vice President, CMC and Manufacturing
Role CMC development, manufacturing, quality and regulatory. Build and implement development and manufacturing strategies to bring Invetx’s transformative biotherapeutics programs to the animal health market.
Experience 20+ years of technical and leadership experience in biologics CMC development and manufacturing of novel biologics and biosimilars including cytokines, monoclonal antibodies, bispecifics, antibody drug conjugates, peptibodies, and Fc fusion proteins.
Supported 20+ IND stage programs, multiple BLA regulatory filings and successful approvals of human biotherapeutics products.
MacroGenics, NexImmune, Hospira/Pfizer and Amgen
Education PhD, Pharmaceutical Sciences, University of Colorado Health Sciences Center, Denver, US
BS Pharmacy, Chennai Medical College, Chennai, India
Lean Six Sigma Green Belt
Robert Zolynas Vice President, Clinical and Regulatory Affairs
Clinical and Regulatory Affairs, dedicated to developing Invetx’s portfolio of innovative veterinary biotherapeutics while defining global regulatory registration strategies and leading global clinical trials generating clinical evidence to obtain regulatory approvals.
25 years of R&D management experience in the Animal Health and Human Pharma Industries including senior leadership roles; focused on bringing innovative veterinary and human pharma medicines to the market.
Implementing state-of-the-art manufacturing and development technologies to bring pioneering biotherapeutics to animal health.
20 years of experience developing biotherapeutics. Lead development teams for the production of several novel biotherapeutics (e.g. biosimilars, antibody-drug conjugates, highly glycosylated fusion proteins, TGF-beta proteins). Experience spans the initial IND for luspatercept as well as characterization for the commercialization of the Infuse(TM) Bone Graft.
Oversee and direct discovery, characterization and developability of transformative biotherapeutics for the Animal Health Market.
10+ years of experience in discovery and bioanalytics of protein therapeutics for rare disease, oncology, and infectious disease. Expertise in protein expression, purification, and multi-specific targeting.
Education PhD in Genetics, GSBS, Tufts University
BS in Molecular and Cell Biology, University of Connecticut
Role Providing laboratory support to Director of Discovery in characterization and developability of transformative biotherapeutics for the animal health market.
Experience 4 years in academic research characterizing protein structure to understand enzyme catalysis and protein-protein interactions associated with various cancers, neurodegenerative diseases and rare disorders. Currently finishing accelerated master’s degree in Biochemistry and Molecular Biology.
Education BA in Biochemistry and Molecular Biology, Carlson School of Chemistry, Clark University, MA
Scientific Advisor, Ad-hoc consultant
Advisor and consultant to Invetx from the ideation stage of the company transitioning to membership on the Scientific Advisory Board.
Head of the Rare Diseases Drug Discovery Unit at Takeda
Two decades of experience in human pharmaceutical development (Pfizer, Shire/Takeda), startups (Physiome Sciences) and academic research (Asst. Professor, University of Texas Southwestern Medical Center in Dallas) studying basic biological questions underpinning biology in multiple diseases and development of therapeutic approaches to address them.
PhD in Neurobiology, Northwestern University, USA
BEng Electronics & Communication Engineering, University of Madras, India
Head (SVP) of the Global Large Molecules Research Platform, Sanofi
20+ years of experience in biologics CMC (chemistry, manufacturing and controls) at Genzyme and Sanofi, from cell line development through GMP drug product manufacturing. Supported the development and commercialization of several biologics currently on the market.
PhD in Biophysical Chemistry, Cornell University
Bachelor of Arts, Biology and Chemistry, University of Vermont
Member of supervisory boards, animal health industry expert.
Experience 25 years of experience in the Animal Health industry. Leading the development of Boehringer Ingelheim’s animal health business from a niche player to a global leader, with final role as Member of the Board of Managing Directors of Boehringer Ingelheim Corporation. Broad experience in strategy and business development, change management as well as management of a global organization.
Managing Partner, Anterra Capital
Founder and Managing Partner at Anterra Capital, currently leading their US office and Life Sciences investment team.
15+ years of consulting and investment experience initially in industrial biotech with McKinsey & Company and Atlas Venture, then more recently at Anterra Capital where his investment portfolio focuses on the application of life sciences technologies across agriculture, animal health, and nutritional wellness.
Senior Vice President, Research, Tekla Capital
Responsible for investment research and due diligence in the biotechnology, medical device, and diagnostic areas. Serves as a member of the team responsible for making investments on behalf of the Funds.
20+ years investment experience in biotech and healthcare.
BS in Mathematics
MD Tufts University
MBA Tufts University
Experience Partner in Novo Holdings’ growth equity investment area (Novo Growth) currently leading activities within food, agriculture, industrials, and bio-manufacturing in North America. Experience across agriculture, chemicals, consumer products, and healthcare on biotechnology strategy and operational topics; business building and corporate development roles in both Denmark and the U.S.
Previous Novozymes, McKinsey & Co.
Education MBA, Columbia Business School
BA, Northwestern University